Abstract
1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have